• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新辅助放化疗后局部进展期直肠癌的 T 分期降期与肿瘤特征调整后复发率降低无关。

T-stage downstaging of locally advanced rectal cancer after neoadjuvant chemoradiotherapy is not associated with reduced recurrence after adjusting for tumour characteristics.

机构信息

Colorectal Surgery Unit, Royal Melbourne Hospital, Melbourne, Victoria, Australia.

Department of Surgery, The University of Melbourne, Melbourne, Victoria, Australia.

出版信息

J Surg Oncol. 2022 Sep;126(4):728-739. doi: 10.1002/jso.26932. Epub 2022 May 30.

DOI:10.1002/jso.26932
PMID:35635190
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9543614/
Abstract

BACKGROUND AND OBJECTIVES

Prior studies examining prognostic outcomes of locally advanced rectal adenocarcinomas achieving a complete pathological response following neoadjuvant chemoradiotherapy (nCRT) did not adjust for adverse prognostic factors in multivariate analyses and account for magnetic resonance imaging tumour staging inaccuracy pre-nCRT. We aimed to clarify prognostic outcomes in mT3 rectal adenocarcinomas with ypT-downstaging post-nCRT in robust adjusted analyses.

METHODS

Retrospective analysis of prospectively-collected clinical data from 528 mT3 rectal adenocarcinomas ≤12 cm from the anal verge, any N-stage, no metastases, post-nCRT following total mesorectal excision (TME). Recurrence outcomes (local and distant combined) of tumours with complete ypT-downstaging (ypT0) post-nCRT before TME compared with no ypT-downstaging (≥ypT3) were examined using multivariate Cox regression, adjusting for confounders and accounting for pre-nCRT mT3-staging inaccuracy using bootstrapping.

RESULTS

Complete ypT-downstaging was achieved in of 17.6% tumours and correlated strongly with complete pathological response. Complete ypT-downstaging was not associated with reduced recurrence hazards compared with no ypT-downstaging (hazard ratio = 0.60; 95% confidence interval [CI]: 0.23-1.56; p = 0.30). Lymphovascular invasion (LVI) and ypN+ve increased recurrence hazards by 1.8-fold (95% CI: 1.10-2.79; p = 0.02) and 2.3-fold (95% CI: 1.48-3.54; p = 0.0002), respectively.

CONCLUSION

Complete ypT-downstaging was not associated with reduced recurrence after adjusting for confounders and accounting for mT3-staging inaccuracy, even in the absence of adverse prognostic factors (ypN+, LVI).

摘要

背景与目的

先前研究检查了新辅助放化疗(nCRT)后完全病理缓解的局部晚期直肠腺癌的预后结果,但在多变量分析中未调整不利的预后因素,也未考虑 nCRT 前磁共振成像肿瘤分期不准确的问题。我们旨在通过稳健的调整分析阐明 nCRT 后 ypT 降期的 mT3 直肠腺癌的预后结果。

方法

对 528 例距肛门 12cm 以内的 mT3 直肠腺癌的前瞻性收集的临床数据进行回顾性分析,这些肿瘤为任何 N 期,无转移,接受 nCRT 后行全直肠系膜切除术(TME)。使用多变量 Cox 回归分析 nCRT 后完全 ypT 降期(ypT0)与无 ypT 降期(≥ypT3)的肿瘤在 TME 前的局部和远处联合复发结果,通过 bootstrapping 调整混杂因素并考虑 nCRT 前 mT3 分期不准确的情况。

结果

17.6%的肿瘤达到完全 ypT 降期,与完全病理缓解密切相关。与无 ypT 降期相比,完全 ypT 降期并未降低复发风险(风险比=0.60;95%置信区间[CI]:0.23-1.56;p=0.30)。淋巴管侵犯(LVI)和 ypN+增加了 1.8 倍(95%CI:1.10-2.79;p=0.02)和 2.3 倍(95%CI:1.48-3.54;p=0.0002)的复发风险。

结论

在调整混杂因素和考虑 mT3 分期不准确的情况下,即使没有不利的预后因素(ypN+、LVI),完全 ypT 降期也与复发后风险降低无关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f426/9543614/b0b3cf0250d7/JSO-126-728-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f426/9543614/2bbb5f3b5c63/JSO-126-728-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f426/9543614/b0b3cf0250d7/JSO-126-728-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f426/9543614/2bbb5f3b5c63/JSO-126-728-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f426/9543614/b0b3cf0250d7/JSO-126-728-g002.jpg

相似文献

1
T-stage downstaging of locally advanced rectal cancer after neoadjuvant chemoradiotherapy is not associated with reduced recurrence after adjusting for tumour characteristics.新辅助放化疗后局部进展期直肠癌的 T 分期降期与肿瘤特征调整后复发率降低无关。
J Surg Oncol. 2022 Sep;126(4):728-739. doi: 10.1002/jso.26932. Epub 2022 May 30.
2
The Prognostic Effects of Clinicopathological Features on Rectal Cancer Patients undergoing Neoadjuvant Chemoradiotherapy.临床病理特征对接受新辅助放化疗的直肠癌患者的预后影响
J Coll Physicians Surg Pak. 2021 Apr;31(4):422-428. doi: 10.29271/jcpsp.2021.04.422.
3
The combination of early treatment response and ypT stage is a novel metric to stage rectal cancer patients treated with neoadjuvant chemoradiotherapy.早期治疗反应与ypT分期相结合是对接受新辅助放化疗的直肠癌患者进行分期的一种新指标。
Oncotarget. 2017 Jun 6;8(23):37845-37854. doi: 10.18632/oncotarget.14708.
4
Factors influencing downstaging after neoadjuvant long-course chemoradiotherapy in rectal carcinoma.影响直肠癌新辅助长程放化疗降期的因素。
Int J Colorectal Dis. 2022 Jun;37(6):1355-1365. doi: 10.1007/s00384-022-04174-y. Epub 2022 May 11.
5
Comparative analysis of lymph node metastases in patients with ypT0-2 rectal cancers after neoadjuvant chemoradiotherapy.新辅助放化疗后 ypT0-2 期直肠癌患者的淋巴结转移比较分析。
Dis Colon Rectum. 2013 Feb;56(2):135-41. doi: 10.1097/DCR.0b013e318278ff8a.
6
[Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].巩固性新辅助治疗或全新辅助治疗后低位直肠癌的保直肠手术:初步报告
Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Mar 25;23(3):281-288. doi: 10.3760/cma.j.cn.441530-20200228-00096.
7
[Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].局部晚期直肠癌患者新辅助治疗与全新辅助治疗的短期疗效及围手术期安全性比较
Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Mar 25;23(3):274-280. doi: 10.3760/cma.j.cn.441530-20190819-00312.
8
Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis.与新辅助长疗程放化疗相比,术前序贯短疗程放疗联合FOLFOX化疗改善直肠癌患者的转移和无病生存率:配对分析结果
Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):417-426. doi: 10.1016/j.ijrobp.2017.05.048. Epub 2017 Jun 6.
9
Pretreatment MRI-detected extramural venous invasion as a prognostic and predictive biomarker for neoadjuvant chemoradiotherapy in non-metastatic rectal cancer: a propensity score matched analysis.治疗前MRI检测到的壁外静脉侵犯作为非转移性直肠癌新辅助放化疗的预后和预测生物标志物:一项倾向评分匹配分析
Eur Radiol. 2024 Jun;34(6):3686-3698. doi: 10.1007/s00330-023-10300-3. Epub 2023 Nov 23.
10
The clinical relevance of adjuvant chemotherapy in locally advanced rectal cancer patients achieving near pathological complete response following neoadjuvant chemoradiotherapy: Insights from ypT stage.新辅助放化疗后达到接近病理完全缓解的局部晚期直肠癌患者辅助化疗的临床相关性:基于ypT分期的见解
Eur J Surg Oncol. 2024 Apr;50(4):108001. doi: 10.1016/j.ejso.2024.108001. Epub 2024 Feb 8.

引用本文的文献

1
Analysis of clinical and pathological prognostic factors of survival in rectal adenocarcinoma treated with preoperative radiochemotherapy.术前放化疗治疗直肠腺癌生存的临床及病理预后因素分析
Acta Cir Bras. 2025 Feb 10;40:e401125. doi: 10.1590/acb401125. eCollection 2025.

本文引用的文献

1
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.局部晚期直肠癌患者的 FOLFIRINOX 新辅助化疗和术前放化疗(UNICANCER-PRODIGE 23):一项多中心、随机、开放标签、III 期临床试验。
Lancet Oncol. 2021 May;22(5):702-715. doi: 10.1016/S1470-2045(21)00079-6. Epub 2021 Apr 13.
2
Accuracy of Magnetic Resonance Imaging in Staging Rectal Cancer with Multidisciplinary Team: A Single-Center Experience.多学科团队协作下磁共振成像对直肠癌分期的准确性:单中心经验
J Cancer. 2019 Oct 21;10(26):6594-6598. doi: 10.7150/jca.32685. eCollection 2019.
3
Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial.
阿柏西普联合改良FOLFOX6诱导化疗在高危直肠腺癌患者标准放化疗及手术前的疗效:GEMCAD 1402随机临床试验
JAMA Oncol. 2019 Nov 1;5(11):1566-1573. doi: 10.1001/jamaoncol.2019.2294.
4
Association of tumor differentiation and prognosis in patients with rectal cancer undergoing neoadjuvant chemoradiation therapy.接受新辅助放化疗的直肠癌患者肿瘤分化与预后的相关性
Gastroenterol Rep (Oxf). 2019 Aug;7(4):283-290. doi: 10.1093/gastro/goy045. Epub 2018 Dec 22.
5
Predictors and Risk Factors of Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Population-Based Analysis.直肠癌新辅助放化疗后病理完全缓解的预测因素和风险因素:一项基于人群的分析
Front Oncol. 2019 Jun 13;9:497. doi: 10.3389/fonc.2019.00497. eCollection 2019.
6
Organ Preservation Among Patients With Clinically Node-Positive Rectal Cancer: Is It Really More Dangerous?临床淋巴结阳性直肠癌患者的器官保存:真的更危险吗?
Dis Colon Rectum. 2019 Jun;62(6):675-683. doi: 10.1097/DCR.0000000000001337.
7
Correlation between tumor microenvironment-associated factors and the efficacy and prognosis of neoadjuvant therapy for rectal cancer.肿瘤微环境相关因素与直肠癌新辅助治疗疗效及预后的相关性
Oncol Lett. 2019 Jan;17(1):1062-1070. doi: 10.3892/ol.2018.9682. Epub 2018 Nov 9.
8
Is adjuvant chemotherapy necessary for locally advanced rectal cancer patients with pathological complete response after neoadjuvant chemoradiotherapy and radical surgery? A systematic review and meta-analysis.新辅助放化疗及根治性手术后达到病理完全缓解的局部晚期直肠癌患者是否需要辅助化疗?一项系统评价与Meta分析。
Int J Colorectal Dis. 2019 Jan;34(1):113-121. doi: 10.1007/s00384-018-3181-9. Epub 2018 Oct 27.
9
Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.直肠癌临床实践指南(NCCN 肿瘤学版)2018 年第 2 版
J Natl Compr Canc Netw. 2018 Jul;16(7):874-901. doi: 10.6004/jnccn.2018.0061.
10
Nodal Disease in Rectal Cancer Patients With Complete Tumor Response After Neoadjuvant Chemoradiation: Danger Below Calm Waters.新辅助放化疗后肿瘤完全缓解的直肠癌患者的淋巴结疾病:平静水面下的危险
Dis Colon Rectum. 2017 Dec;60(12):1260-1266. doi: 10.1097/DCR.0000000000000947.